Lawrence A. Kenyon's most recent trade in Outlook Therapeutics Inc was a trade of 210,078 Stock Option (Right to Buy) done . Disclosure was reported to the exchange on July 21, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Outlook Therapeutics Inc | Lawrence A. Kenyon | Director, Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Jul 2026 | 210,078 | 210,078 | - | - | Stock Option (Right to Buy) | |
| Outlook Therapeutics Inc | Lawrence A. Kenyon | Director, Chief Financial Officer | Purchase of securities on an exchange or from another person at price $ 5.69 per share. | 26 Sep 2024 | 5,000 | 5,946 (0%) | 0% | 5.7 | 28,446 | Common Stock |
| Outlook Therapeutics Inc | Lawrence A. Kenyon | Director, CHIEF FINANCIAL OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Mar 2024 | 12,500 | 12,500 | - | - | Stock Option (Right to Buy) |